ERDOTIN ® Erdosteina

ERDOTIN® is a thiopronine based drug

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ERDOTIN ® Erdosteina

ERDOTIN® is used as a mucolytic agent in throat disorders both acute and chronic.

Mechanism of action ERDOTIN ® Erdosteina

ERDOTIN® is a medicinal product based on Erdosteine, an active ingredient with marked mucolytic and antioxidant activity.

Taken orally, it is rapidly absorbed by the enteric mucosa, reaching the plasma peak after about 30-60 minutes, to be subsequently metabolized in the active components and distributed in a circle.

Through the circulatory stream, Erdosteina and its active metabolites reach the broncho-pulmonary environment, where concentrated in clinically relevant quantities, perform their therapeutic action both by thinning the bronchial mucus by breaking the disulfide bridges of the mucoproteins, and by protecting the cells of the respiratory mucosa from the damaging action carried out by the reactive oxygen species.

The greater fluidity of these secretions is also accompanied by an increase in the volume of the same, which obviously facilitates the elimination through the sputum.

Studies carried out and clinical efficacy

HEPATOPROTECTIVE ACTION OF ERDOSTEIN

Toxicol Ind Health. 2012 Oct 15.

Work that demonstrates how the antioxidant potential of Erdosteine can be useful in preventing liver damage induced by paracetamol hyper-intake, when taken promptly

ERDOSTEINE CHANGES THE CHEMICAL-PHYSICAL PROPERTIES OF THE ESREATED

Lung. 1990; 168 (5): 285-93.

An Italian study that demonstrates how Erdosteina, in addition to facilitating the elimination of bronchial secretions, can also modify the chemical-physical characteristics of the sputum, increasing the presence of IgA and albumin and significantly improving its fluidity.

THE EFFECT OF THE ERDOSTEIN ON THE RESPIRATORY EPITELIUM

Respiration. 1991; 58 (2): 91-4.

Work demonstrating that Erdosteine can significantly improve the mucociliary activity of the respiratory epithelium, even in patients with chronic bronchitis, facilitating the excretion of sputum and ensuring better control of associated symptoms.

Method of use and dosage

ERDOTIN®

Erdosteine 300 mg tablets;

Erdosteine 300 mg capsules;

Granulated for 225 mg oral suspension of Erdosteine.

The dosage and intake schedule for Erdosteine should be defined by your doctor based on the patient's overall health and the severity of his / her clinical picture.

In general, the intake of 1 tablet, capsule or sachet 2-3 times a day is sufficient in adults to guarantee a prompt remission of symptoms in a few days of treatment.

Warnings ERDOTIN ® Erdosteina

The use of ERDOTIN® must necessarily be preceded by a careful medical examination in order to clarify the possible presence of contraindications to the use of the drug or of situations generally incompatible with such therapy.

It should be remembered that Erdosteine's ability to increase the volume of bronchial secretions could be potentially dangerous due to the risk of obstruction of the respiratory tract in patients with reduced expectoration capacity.

ERDOTIN® in sachet contains Sucrose and Aspartame resulting therefore contraindicated in patients with fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency and phenylketonuria.

The presence of lactose also extends the aforementioned contraindications also to patients suffering from galactose intolerance, lactase enzyme deficiency and glucose-galactose malabsorption syndrome.

PREGNANCY AND BREASTFEEDING

From the moment in which the safety of Erdosteine for the health of the fetus and the infant has not yet been evaluated, it would be appropriate to extend the aforementioned contraindications to the use of ERDOTIN® also to pregnancy and the subsequent period of breastfeeding.

Interactions

At the moment active ingredients are not known to interfere with the activity and safety of Erdosteina.

Contraindications ERDOTIN ® Erdosteina

The use of ERDOTIN® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in patients with active peptic ulcer, in patients with phenylketonuria, in pediatric patients and in patients with impaired renal function.

Undesirable effects - Side effects

The use of ERDOTIN® could determine the onset of adverse reactions mainly of the gastro-enteric type, fortunately limited to the period of intake of the drug.

Adverse reactions related to hypersensitivity were generally rarer.